期刊
GENETICS IN MEDICINE
卷 23, 期 12, 页码 2433-2442出版社
ELSEVIER SCIENCE INC
DOI: 10.1038/s41436-021-01290-y
关键词
-
资金
- Roche
- University Hospital of Dijon [RG84782]
This study aimed to establish the tolerability and efficacy of low-dose taselisib in PROS patients, with functional improvement observed but safety concerns preventing long-term use. Two out of 19 enrolled patients experienced dose-limiting toxicities leading to early trial termination, while no significant reduction in affected tissue volume was observed in the study. Despite some clinical improvements reported by participants, the overall safety profile of low-dose taselisib raises doubts about its long-term viability.
Purpose PIK3CA pathogenic variants in the PIK3CA-related overgrowth spectrum (PROS) activate phosphoinositide 3-kinase signaling, providing a rationale for targeted therapy, but no drug has proven efficacy and safety in this population. Our aim was to establish the six-month tolerability and efficacy of low-dose taselisib, a selective class I PI3K inhibitor, in PROS patients. Methods Patients over 16 years with PROS and PIK3CA pathogenic variants were included in a phase IB/IIA multicenter, open-label single-arm trial (six patients at 1 mg/day of taselisib, then 24 at 2 mg/day). The primary outcome was the occurrence of dose limiting toxicity (DLT). Efficacy outcomes were the relative changes after treatment of (1) tissue volume at affected and unaffected sites, both clinically and on imaging; (2) cutaneous vascular outcomes when relevant; (3) biologic parameters; (4) quality of life; and (5) patient-reported outcomes. Results Among 19 enrolled patients, 2 experienced a DLT (enteritis and pachymeningitis) leading to early trial termination (17 treated, 10 completed the study). No serious adverse reaction occurred in the 1 mg cohort (n = 6). No significant reduction in affected tissue volume was observed (mean -4.2%; p = 0.81; SD 14.01). Thirteen (76.4%) participants reported clinical improvement (pain reduction, chronic bleeding resolution, functional improvement). Conclusion Despite functional improvement, the safety profile of low-dose taselisib precludes its long-term use.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据